Aastrom Adds Revenues Through $6.5M Regen Med Buy From Sanofi
This article was originally published in The Pink Sheet Daily
Executive Summary
The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.